Business Description
![Nektar Therapeutics Nektar Therapeutics logo](https://static.gurufocus.com/logos/0C00000BR5.png?14)
Nektar Therapeutics
NAICS : 325412
SIC : 2834
ISIN : US6402681083
Share Class Description:
FRA:ITH: Ordinary SharesCompare
Compare
Traded in other countries / regions
NKTR.USAITH.Germany0UNL.UKNKTR.Mexico IPO Date
1994-05-03Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.42 | |||||
Equity-to-Asset | 0.23 | |||||
Debt-to-Equity | 1.41 | |||||
Debt-to-EBITDA | -0.77 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -14.34 | |||||
Beneish M-Score | 5.68 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -17.9 | |||||
3-Year EBITDA Growth Rate | 16.5 | |||||
3-Year EPS without NRI Growth Rate | 30.5 | |||||
3-Year FCF Growth Rate | 17.2 | |||||
3-Year Book Growth Rate | -51.5 | |||||
Future 3-5Y EPS without NRI Growth Rate | 7.61 | |||||
Future 3-5Y Total Revenue Growth Rate | -9.33 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 40.23 | |||||
9-Day RSI | 43.04 | |||||
14-Day RSI | 43.89 | |||||
6-1 Month Momentum % | 119.5 | |||||
12-1 Month Momentum % | 105.59 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.15 | |||||
Quick Ratio | 4.9 | |||||
Cash Ratio | 4.73 | |||||
Days Inventory | 158.77 | |||||
Days Sales Outstanding | 7.49 | |||||
Days Payable | 59.55 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2 | |||||
Shareholder Yield % | -5.45 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 59.22 | |||||
Operating Margin % | -145.03 | |||||
Net Margin % | -190.09 | |||||
FCF Margin % | -188.11 | |||||
ROE % | -127.63 | |||||
ROA % | -42.69 | |||||
ROIC % | -157.07 | |||||
ROC (Joel Greenblatt) % | -409.14 | |||||
ROCE % | -42.11 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.84 | |||||
PB Ratio | 3.12 | |||||
Price-to-Tangible-Book | 3.13 | |||||
EV-to-EBIT | -0.59 | |||||
EV-to-EBITDA | -0.61 | |||||
EV-to-Revenue | 0.96 | |||||
EV-to-Forward-Revenue | 1.05 | |||||
EV-to-FCF | -0.51 | |||||
Price-to-Median-PS-Value | 0.28 | |||||
Price-to-Net-Current-Asset-Value | 8.19 | |||||
Price-to-Net-Cash | 35.5 | |||||
Earnings Yield (Greenblatt) % | -169.49 | |||||
FCF Yield % | -70.57 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nektar Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 86.255 | ||
EPS (TTM) (€) | -0.834 | ||
Beta | 1.62 | ||
Volatility % | 85.72 | ||
14-Day RSI | 43.89 | ||
14-Day ATR (€) | 0.038528 | ||
20-Day SMA (€) | 1.1071 | ||
12-1 Month Momentum % | 105.59 | ||
52-Week Range (€) | 0.3901 - 1.687 | ||
Shares Outstanding (Mil) | 184.08 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Nektar Therapeutics Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Nektar Therapeutics Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Nektar Therapeutics Frequently Asked Questions
What is Nektar Therapeutics(FRA:ITH)'s stock price today?
The current price of FRA:ITH is €1.07. The 52 week high of FRA:ITH is €1.69 and 52 week low is €0.39.
When is next earnings date of Nektar Therapeutics(FRA:ITH)?
The next earnings date of Nektar Therapeutics(FRA:ITH) is 2024-11-07 Est..
Does Nektar Therapeutics(FRA:ITH) pay dividends? If so, how much?
Nektar Therapeutics(FRA:ITH) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |